Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy

Basit Öğe Kaydı
dc.authoridEroz, Pinar/0000-0002-6791-956X
dc.authoridOzer, Omer/0000-0003-0329-0931
dc.contributor.authorOzer, Omer
dc.contributor.authorDogan, Levent
dc.contributor.authorBaysal, Zeki
dc.contributor.authorBasir, Hakan
dc.contributor.authorCiftci, Ali Turker
dc.contributor.authorEroz, Pinar
dc.contributor.authorGuclu, Emin Serbuelent
dc.date.accessioned2024-11-07T13:32:47Z
dc.date.available2024-11-07T13:32:47Z
dc.date.issued2024
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractBackground The aim of this study was to evaluate the clinical significance of blood-cell associated inflammation markers in patients with sickle cell disease (SCD) and sickle cell retinopathy (SCR). Methods Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), systemic immune inflammation index (SIII), systemic inflammation response index (SIRI), systemic inflammation modulation index (SIMI) and aggregate systemic inflammation index (AISI) were calculated. This study included 45 healthy controls (Group 1) and 100 SCD (Group 2). Patients in Group 2 were then divided into two groups: without SCR (Group 3) and with SCR (Group 4), and patients with SCR (Group 4) were further divided into two groups: non-proliferative sickle cell retinopathy (NPSCR) (Group 5) and proliferative sickle cell retinopathy (PSCR) (Group 6). Results The mean values for NLR, PLR, SIII, SIRI, AISI, and SIMI were significantly higher in Group 2 compared to Group 1 (p = 0.011 for NLR, p = 0.004 for SIII, and p < 0.001 for others). Furthermore, AISI and SIMI parameters demonstrated statistically significant discriminatory power to distinguish Group 5 from Group 6 (p = 0.0016 and p = 0.0006, respectively). Conclusion Given the critical role of inflammatory mechanisms in the pathogenesis of SCD and its related complications, the assessment of blood-cell-associated inflammatory markers may present a pragmatic and advantageous approach to the clinical oversight and therapeutic intervention of SCD.
dc.description.sponsorshipScientific and Technological Research Council of Turkiye (TUEBITAK)
dc.description.sponsorshipOpen access funding provided by the Scientific and Technological Research Council of Turkiye (TUEBITAK). No funding was received for this research.Open access funding provided by the Scientific and Technological Research Council of Turkiye (TUEBITAK).
dc.identifier.doi10.1007/s00417-024-06569-9
dc.identifier.issn0721-832X
dc.identifier.issn1435-702X
dc.identifier.pmid38976013
dc.identifier.scopus2-s2.0-85197700903
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s00417-024-06569-9
dc.identifier.urihttps://hdl.handle.net/11480/15618
dc.identifier.wosWOS:001265419700001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofGraefes Archive For Clinical and Experimental Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectAnemia
dc.subjectComplete blood count
dc.subjectDisease
dc.subject& Idot;nflammation
dc.subjectRetinopathy
dc.subjectSickle cell
dc.titleEvaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu